This research aimed to develop and evaluate a new oral formulation for Lornoxicam.
Developed biphasic-release multiple-unit tablets (MUTs)
Assessed rapid onset and sustained delivery characteristics
Evaluated dose flexibility in laboratory settings
Biphasic-release MUTs provide rapid onset of action
Enabled sustained delivery of Lornoxicam
Demonstrated reliable dose flexibility for effective therapy
Abstract
The developed biphasic-release MUTs provide rapid onset, sustained LOX delivery, and reliable dose flexibility, representing a promising oral formulation for LOX therapy.